Liver Cancer Vaccines
Creative Biolabs is a world leader in the field of cancer vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best services for vaccine development against liver cancer and guarantee the finest results for our customers all over the world.
Liver Cancer
Liver cancer is a major health problem, with more than 850,000 new cases annually worldwide. This neoplasm is currently the second leading cause of cancer-related death globally. Among all primary liver cancers, hepatocellular carcinoma (HCC) is the most common neoplasm, accounting for approximately 90% of cases. Treatments that have been shown to extend the life expectancy of patients with HCC include surgical resection, liver transplantation, radiofrequency ablation, chemoembolization, and the multi-kinase inhibitor sorafenib. Complete tumor ablation is attempted in around 40% of patients, usually in the early and very early stages, by means of surgical (resection and transplantation) and percutaneous (radiofrequency or ethanol injection) techniques. Patients with more advanced disease still restricted to the liver usually receive trans-arterial therapies including chemoembolization and radioembolization. Local treatments inducing tumor necrosis and/or massive apoptosis offer an opportunity to be combined with immunotherapy approaches.
HBV Vaccines
Hepatitis B virus (HBV) infection is the main cause of the morbidity and mortality of hepatitis. Hepatitis B is an infectious liver disease that comes from hepatitis B virus infection. Acute infection may last for several weeks. If the virus stays in the body, it can cause severe chronic infections, leading to liver damage, liver cancer, and death. But HBV infection can be prevented. In uninfected individuals, HBV vaccines are safe and effective in preventing the spread of the disease. Countries with successful vaccination have been able to significantly reduce the prevalence of HBV.
Therapeutic Vaccines for Liver Cancer
The global aim of therapeutic vaccines is to stimulate a specific cellular immune response against tumor-associated epitopes. Different strategies have been tested in HCC patients, including the use of peptides, proteins, RNA, and cell lines as the source of antigen. So far, peptide vaccination has relied on the oncofetal antigens, alpha-fetoprotein, and glypican-3 (GPC-3). The intradermal injection of four different alpha-fetoprotein-derived peptides induced specific circulating T cell responses in patients with HCC. Similarly, a vaccination protocol based on GPC-3 peptides tested in patients with unresectable HCC was shown to induce peripheral GPC-3-specific cytotoxic T lymphocytes and to increase the CD8+ T lymphocyte infiltration in tumor biopsies.
An extensively tested strategy for therapeutic vaccination is the use of autologous DCs pulsed with tumor antigens. DCs are able to boost both CD4+ and CD8+ T lymphocyte responses, but this approach may be compromised by an impairment in antigen presentation by cancer patient derived APCs in which ineffective tumor antigen processing has been reported. A number of clinical trials have tested the therapeutic efficacy of DCs pulsed both with single or multiple tumor antigens, including alpha-fetoprotein, GPC-3, heat shock protein 70, viral hepatitis antigens, tumor cell line lysate, or autologous tumor lysate. Strong antigen-specific responses were observed in most cases but without significant clinical correlates.
Creative Biolabs is a leader in the field of vaccine development and has focused on the cancer vaccines for years. We have experts who are able to help you with the development of the liver cancer vaccines. If you are interested in our services, please contact us for more details.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
